Equfina ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	2

6. パーキンソン病

---

臨床試験数 : 2,298 /  薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05225324 (ClinicalTrials.gov)	June 3, 2021	26/1/2022	A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)	Equfina Tablet 50 mg Post Marketing Surveillance Protocol	Parkinson Disease;Liver Diseases;Renal Insufficiency	Drug: Equfina 50 mg	Eisai Korea Inc.	NULL	Recruiting	18 Years	N/A	All	600		Korea, Republic of
2	NCT04724109 (ClinicalTrials.gov)	October 14, 2020	21/1/2021	A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)	Protocol for Study EQF01S: General Drug Use-Results Observational Study of Equfina® TABLETS 50 mg Observational Study on the Incidences of Adverse Drug Reactions in Patients With Parkinson's Disease (Including Patients With Hepatic Impairment)	Parkinson Disease	Drug: Equfina	Eisai Co., Ltd.	NULL	Recruiting	N/A	N/A	All	1000		Japan